A Prospective, Multi-center, Placebo-controlled, Randomized, Double-blind, Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo Administered as Oral Daily Dose for Three Months in Patients Suffering From Overactive Bladder.
Sponsors and Collaborators
Kwang Dong Pharmaceutical co., ltd.
Contact
MS Choo
mschoo@amc.seoul.kr
ClinicalTrials.gov Identifier
NCT01458197